Article

DME drug to begin phase I trial this year

Vancouver-iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME).

Vancouver-iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME). The biotechnology company plans to begin its phase I clinical trial for diffuse DME during the first half of this year.

The second-generation antisense drug targets c-Raf kinase messenger RNA, potentially decreasing the edema in the retina by decreasing the signaling of various growth factors, including VEGF, which signal through the c-Raf kinase/MAP kinase pathway.

Designed and discovered by Isis Pharmaceuticals Inc., the drug was licensed to iCo Therapeutics in August 2005.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.